Bayer: GALILEO Trial Halted Early Due To Increased Mortality, Events - Docwire News
The GALILEO Trial: Inova Researchers Study New Drug Therapy for Heart Patients - Inova Newsroom
OAC in TAVR: Failed Galileo
Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR? | tctmd.com
Bayer: GALILEO Trial Halted Early Due To Increased Mortality, Events - Docwire News
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study - ScienceDirect
The ATLANTIS Randomized Trial: Apixaban Versus Standard of Care After TAVI - Cardiac Interventions Today
Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR | tctmd.com
Results of the GALILEO trial (intention-to-treat analysis). | Download Scientific Diagram
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | JACC: Cardiovascular Interventions
Results of the GALILEO trial (intention-to-treat analysis). | Download Scientific Diagram
GALILEO Trial
Galileo
PDF) Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
GALILEO 4D - STUDY DESIGN
A controlled trial of rivaroxaban after transcatheter aortic-valve replacement (GALILEO)
Clinical Trial Results in MEfRVO | EYLEA® (aflibercept) Injection
GALILEO Trial
On The Behalf of The GALILEO Investigators - ppt download
Galileo Research Fact Sheet #48: Can Galileo Therapy increase bone mass and decrease fracture risk? - Novotec Medical und Stratec Medizintechnik GmbH
Rivaroxaban-based antithrombotic strategy vs antiplatelet-based strategy after TAVR to optimize clinical outcomes: GALILEO
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement | BMJ Open
